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0.50-NUR; 0.42-PH) and low or insigniﬁcant for Pain (0.32-
FAM; 0.40-NUR; 0.18-PH) and Anxiety/Depression (0.26-FAM;
0.28-NUR; 0.14-PH). The variables associated to the difference
between the VAS score of patient and carriers were studied using
lineal regression. Mean (S.D) PCS and MCS of caregivers were
48.4 (13.8) and 48.0 (11.3). Multiple regression analysis showed
that higher ZS and older patient age were associated to lower
PCS of the caregiver (R2 = 0.15; p < 0.001) and that higher ZS
and lower FSS of the caregiver, and lower MCS of the patient
were associated to lower MCS of the caregiver (R2 = 0.29; p <
0.001). Lower FSS, PCS and MCS of the caregiver and higher
age and lower PCS and MCS of the patient were associated to
higher score on ZS of caregivers (R2 = 0.49; p < 0.001). CON-
CLUSIONS: Agreement between patients and carriers was mod-
erate for “objective” dimensions of HRQOL and low for
“subjective” ones. HRQoL of FAM is slightly worse than that
of the general population. The burden of FAM depends on per-
ceived social support, patient’s age and health status of carrier
and patient.
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OBJECTIVES: To review quality of life (QoL) questionnaire use
and methods for handling missing data in published chemother-
apy studies [2000–2005 (Jan)] of non-small cell lung cancer
(NSCLC). METHODS: We conducted a detailed search of the
published literature on quality of life, NSCLC, and chemother-
apy, excluding studies with limited total sample size (<50).
Thirty-ﬁve studies covering 10 QoL questionnaires and 17
chemotherapy drugs were reviewed. RESULTS: Most studies
were conducted in Europe (primarily Italy and the U.K.), and the
average sample size was 137 patients per treatment arm (range:
16, 406). QoL questionnaires were typically self-administered at
baseline and every 3 weeks thereafter until disease progression
(roughly 2 years duration). The EORTC QLQ-C30 and EORTC
QLQ-LC13 (QLQ-LC13) questionnaires were most often used
in Europe (15 of 24 European studies); however, the FACT-L
questionnaire was commonly used in the U.S. (7 of 13 U.S.
studies). The EORTC QLQ-C30/QLQ-LC13 combination
detected signiﬁcant differences for QoL outcomes in 14 of 15
studies which reported EORTC domain scores, while the FACT-
L detected differences in 3 of 7 studies. Both questionnaires
contain similar domains, but the EORTC QLQ-C30/QLQ-LC13
includes more items on chemotherapy symptoms and FACT-L
includes items on patients’ attitude towards their cancer. Several
studies examined potential non-random bias due to missing data
resulting from death or disease progression. One study detected
conﬂicting results when including (versus excluding) missing
data from their analyses. Another study observed different QoL
results when comparing cycle-to-cycle data at similar time points
rather than study completion data using the last observation
carried forward. CONCLUSIONS: Although EORTC QLQ-
C30/QLQ-LC13 and FACT-L are both widely used, are similar
in content, and can detect differences in NSCLC patients, they
are used preferentially in Europe and the U.S, respectively. Inap-
propriate assumptions concerning the randomness of missing
data can result in biased estimates of QoL.
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OBJECTIVES: To inform coverage decisions regarding drug-
eluting coronary stents by assessing their cost-effectiveness for
particular high-risk patient subgroups. METHODS: The analy-
sis compared the cost-effectiveness of the two drug eluting stents
(DES) available in the UK (Cypher and Taxus) and bare-metal
stents (BMS). A review was undertaken of randomised trials
including one or both of the DES. Individual patient data were
available for some of these trials. The model parameters
extracted from the trials were further revascularisation rates,
undertaken for clinical reasons, either percutaneous interven-
tions or bypass surgery, during follow-up. Three subgroups were
considered on the basis of their higher baseline risk of repeat
revascularisation: small vessels, long lesions and diabetics; a
fourth subgroup without these risk factors was also considered.
The evidence synthesis was implemented as a Bayesian hierar-
chical logistic model. A probabilistic decision model was devel-
oped. RESULTS: Evidence from 15 trials was incorporated into
the synthesis, 5 of which supplied individual patient data. The
probability of repeat percutaneous interventions was lowest with
Cypher and highest with BMS. Both DES had lower probabili-
ties of subsequent bypass surgery than BMS, and the probability
for Taxus was slightly lower than for Cypher. Cost-effectiveness
results were sensitive to the stent prices. At current UK prices
(£908 BMS, £1300 Taxus, £1341 Cypher), Taxus is dominated
by Cypher in diabetic patients and subject to extended domi-
nance in all other subgroups. Cypher has an incremental cost per
QALY gained, compared to BMS, of £13,759, £23,086, £13,740
in patients with small vessels, long lesions and diabetes, respec-
tively. In patients with no risk factors, this increases to £35,865.
CONCLUSIONS: Given existing list prices, Cypher is likely to
be considered more cost-effective than BMS and Taxus in
patients at high baseline risk of further revascularization. This
conclusion may change following any changes in the relative
stent prices.
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OBJECTIVES: Endeavor combines the Driver stent, the drug
ABT-578 and a PC polymer into a new drug-eluting coronary
artery stent (DES) system. As results from long-term trials of
Endeavor are not yet available, economic modeling techniques
must be employed to evaluate the cost-effectiveness of this new
treatment option. The study undertook the ﬁrst assessment of
the cost-effectiveness of Endeavor DES, compared to the Driver
bare-metal stent (BMS), in the treatment of de novo lesions in
native coronary arteries. METHODS: A Markov model was
developed simulating the results of the ENDEAVOR II trial at
nine months follow-up, and extrapolating to ﬁve years using the
BENESTENT I trial. No difference was assumed between the
outcomes with the two stents after the ﬁrst year. The events
modeled were target vessel revascularisations, AMIs, cere-
